We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
ZOLGENSMA IT Novartis Pharmaceuticals Australia Pty Ltd
Product name
ZOLGENSMA IT
Accepted date
Sep-2025
Active ingredients
onasemnogene abeparvovec
Summary of proposed indication
Zolgensma IT (onasemnogene abeparvovec) is an adeno-associated virus (AAV) vector-based gene therapy that is proposed for the treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older.
Application type
C (new indication)
Publication date
Sep-2025